SkipToMainContentPrescribingInformationDLBCLStagesThe4stagesofDLBCL Stagingdescribeshowfarlymphomahasspread.KeepinmindthateventhemostadvancedstagesofdiffuselargeB-celllymphoma(DLBCL)(StageIIIandStageIV)arecommonandcanbetreated.NEXT:GoalsoftreatmentImportantSafetyInformation&IndicationsBacktoTopIndicationsRITUXANHYCELA®(rituximab/hyaluronidasehuman)isaprescriptionmedicineusedtotreatadultswith:FollicularLymphoma(FL)asasingle-agenttherapyinpatientswhosediseaserecurredordidnotrespondtoinitialtreatmentFollicularLymphomaasaninitialtreatmentwithchemotherapyand,inpatientswhoseinitialtreatmentwassuccessful,asasingle-agentfollow-uptherapyFollicularLymphomaasasingleagentfollow-uptherapyforpatientswhodidnotprogressoninitialtreatmentwithCVPchemotherapyDiffuseLargeB-CellLymphoma(DLBCL)asaninitialtreatmentincombinationwithCHOPorotheranthracycline-basedchemotherapyregimensChronicLymphocyticLeukemia(CLL)incombinationwithFCchemotherapyasaninitialtreatmentorasatreatmentafterdiseasehasrecurredYoucanonlyreceiveRITUXANHYCELAafteryoureceiveatleast1fulldoseofintravenous(IV)RITUXAN®(rituximab).ReadtheIVRITUXANMedicationGuideformoreinformationaboutsevereinfusionreactions,whichusuallyhappenduringthefirstdosewithIVRITUXANRITUXANHYCELAisnotforusetotreatmedicalconditionsotherthancancersItisnotknownifRITUXANHYCELAissafeandeffectiveinchildrenWhatisthemostimportantinformationIshouldknowaboutRITUXANHYCELA?RITUXANHYCELAcancauseserioussideeffectsthatcanleadtodeath,including:Severeskinandmouthreactions:TellyourhealthcareproviderorgetmedicalhelprightawayifyougetanyofthesesymptomsatanytimeduringyourtreatmentwithRITUXANHYCELA:painfulsoresorulcersonyourskin,lips,orinyourmouth;blisters;peelingskin;rashorpustulesHepatitisBvirus(HBV)reactivation:BeforeyoureceiveRITUXANHYCELA,yourdoctorwilldobloodteststocheckforHBVinfection.IfyouhavehadhepatitisBorareacarrierofhepatitisBvirus,receivingRITUXANHYCELAcouldcausethevirustobecomeanactiveinfectionagain.HepatitisBreactivationmaycauseseriousliverproblemsincludingliverf

StagingNCBISkiptomaincontentSkiptonavigationResourcesHowToAboutNCBIAccesskeysMyNCBISignintoNCBISignOutNCBIBookshelf.AserviceoftheNationalLibraryofMedicine,NationalInstitutesofHealth.StatPearls[Internet].TreasureIsland(FL):StatPearlsPublishing;2021Jan-.StatPearls[Internet].ShowdetailsTreasureIsland(FL):StatPearlsPublishing;2021Jan-.SearchtermDiffuseLargeBCellLymphomaSandeepA.Padala;AvyaktaKallam.AuthorInformationAuthorsSandeepA.Padala1;AvyaktaKallam2.Affiliations1AugustaUMC/MedicalCollegeofGeorgia2UniversityofNebraskaMedicalCenterLastUpdate:August2,2021.ContinuingEducationActivityDiffuselargeBcelllymphoma(DLBCL)isthemostcommonlymphoma,accountingforabout25%to30%ofallthenon-Hodgkinlymphomas.Ittypicallypresentsasarapidlygrowingmassorenlarginglymphnodesinanodalorextranodalsite.Thoughaggressive,theydorespondwelltosixcyclesofrituximabalongwithcyclophosphamide,doxorubicin,vincristine,andprednisone(R-CHOP).ThisactivityreviewstheevaluationandtreatmentofDLBCLandhighlightstheroleoftheinterprofessionalteaminevaluatingandtreatingpatientswiththiscondition.Objectives:DescribethepathophysiologyoftheBcelllymphomas.Reviewtheworkupofthepatientswithlymphoma.OutlinesthetreatmentofBcelllymphomas,asitdependsnotonlyontheirstagingbutalsoonthetypeofthedisease(indolentoraggressive)andthemolecularsubtype.SummarizetheroleoftheinterprofessionalteammembersinoptimizingcollaborationandcommunicationtoensurepatientswithDLBCLreceivehigh-qualitycare,whichwillleadtobetteroutcomes.Accessfreemultiplechoicequestionsonthistopic.IntroductionLymphomaisthemalignancyofthelymphocytesinthelymphoidsystem,andthey canarise fromBlymphocytesorTlymphocytesorthenaturalkiller(NK)cellsduringtheirdifferentstagesofmaturation.ItcanbeclassifiedintoHodgkinsandNon-Hodgkinslymphoma(NHL). NHLconstitutesabout80%ofalllymphomas.B-cellsareknowntohavefunctionaldiversityandpropertyto transformintomultiplepathways.[1] Due toitsfunctionaldiversity,itrepresentsaheterogeneousgroupofdiseasesvaryingclinicallyandpathologically. Morethan30subty

Systems for staging diffuse large B-cell lymphoma (DLBCL) are provided below, including the World Health Organization (WHO)/Revised European ...ForYouNews&PerspectiveDrugs&DiseasesCME&EducationAcademyVideoDecisionPointEdition:ENGLISHDEUTSCHESPAÑOLFRANÇAISPORTUGUÊSLogInSignUpIt'sFree!Edition:ENGLISHDEUTSCHESPAÑOLFRANÇAISPORTUGUÊSRegisterLogInNoResultsNoResultsForYouNews&PerspectiveDrugs&DiseasesCME&EducationAcademyVideoDecisionPointclosePleaseconfirmthatyouwouldliketologoutofMedscape.Ifyoulogout,youwillberequiredtoenteryourusernameandpasswordthenexttimeyouvisit.LogoutCancelhttps://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cDovL2VtZWRpY2luZS5tZWRzY2FwZS5jb20vYXJ0aWNsZS8yMDA3Nzg5LW92ZXJ2aWV3processing....Drugs&Diseases>OncologyDiffuseLargeB-CellLymphoma(Non-HodgkinLymphoma)Staging Updated:Dec10,2020Author:FranciscoJHernandez-Ilizaliturri,MD;ChiefEditor:MatthewCFoster,MD more...ShareEmailPrintFeedbackCloseFacebookTwitterLinkedInWhatsAppSectionsDiffuseLargeB-CellLymphoma(Non-HodgkinLymphoma)StagingSectionsDiffuseLargeB-CellLymphoma(Non-HodgkinLymphoma)StagingStagingofDiffuseLargeB-CellLymphomaQuestions&AnswersShowAllTablesReferencesStagingofDiffuseLargeB-CellLymphomaSystemsforstagingdiffuselargeB-celllymphoma(DLBCL)areprovidedbelow,includingtheWorldHealthOrganization(WHO)classification[1,2]andtheCotswoldsmodificationoftheAnnArborsystem.RiskstratificationwiththeInternationalPrognosticIndex(IPI)scoreisalsoprovided.[3]WHOclassificationDLBCL,nototherwisespecified(NOS)includesthefollowing:GerminalcenterB-celltypeActivatedB-celltypeOtherformsincludethefollowing:PrimaryDLBCLofthecentralnervoussystem(CNS)PrimarycutaneousDLBCL,legtypeEpstein-Barrvirus(EBV)–positiveDLBCLNOSDLBCLassociatedwithchronicinflammationHumanherpesvirus8(HHV8)–positiveDLBCL,NOSTable.CotswoldsmodificationofAnnArborstagingsystem(OpenTableinanewwindow)StageAreaofInvolvementISinglelymphnodegroupIIMultiplelymphnodegroupsonsamesideofdiaphragmIIMultiplelymphnodegroups

TogglenavigationCOVID-19AboutAboutTheASCOPostEditorialBoardRightsandPermissionsContactSubscribeNewsFDAUpdateJournalSpotlightExpert'sCornerIntheClinicViewByIssueViewAllMeetingsAACR-NCI-EORTCVirtualInternationalConferenceonMolecularTargetsandCancerTherapeutics14thAACRConferenceontheScienceofCancerHealthDisparitiesinRacial/EthnicMinoritiesandtheMedicallyUnderserved2021ASCOQualityCareSymposiumESMOCongress2021SOHO2021CalendarViewAllTopicsBreastCancerLungCancerProstateCancerLymphomaViewAllVideosNewsreelsVideoRoundtablesPodcastsSubscribeAdvertisementChallengesofManagingOlderPatientsWithDiffuseLargeB-CellLymphomaByColetteN.Owens,MDSeptember10,2018AdvertisementColetteN.Owens,MDAsthepopulationcontinuestoage,theinterplaybetweenagingandcancerincreasinglyshowscancertobeadiseaseofolderpeople.Bytheyear2030,therewillbeanincreasedincidenceofnon-Hodgkinlymphoma(NHL)inolderindividuals.1ThemedianageofpatientsdiagnosedwithdiffuselargeB-celllymphoma(DLBCL)is70yearsold,andgiventhesedemographicchanges,oncologistswillincreasinglyberequiredtomanageolderpatientswithDLBCLinthecontextofcomorbidityandage-relatedorgandysfunction.DLBCLisanaggressiveNHLthatiscurablewithfront-linetherapywithananthracycline-basedchemoimmunotherapy,withoverallsurvivalratesof60%to70%.2,3However,thisrepresentsthebestopportunityforcure,asthosewithrelapsedorrefractorydiseaseoftendieofthedisease.StuartM.Lichtman,MDGiventhiscontext,therearesignificantchallengesinoptimizingtherapyforolderpatientsinthecontextofdiseaseandpatientfactors.Fromapracticalstandpoint,theinitialassessmentofolderpatientswithDLBCLisevolvingnotonlytoincludediseasestagingandbiologicriskfactors,butalsooncogeriatricriskassessments.LifeExpectancyCONSIDERATIONOFlifeexpectancyisimportantinchoosingatherapyforolderpatients.Theaverage80-year-oldhasapredictedlifeexpectancyofapproximately5years,andthus,DLBCLismostlikelythegreatestrisktothepatient,exceptforthefrailestpatientswithalifeexpectancyoflessthan1year.4GUESTEDITORGeriatricsfortheOncologistisguesteditedbyStua

Diffuse large B cell lymphoma is the most common subtype of non-Hodgkin lymphoma. ... Staging. See the article on lymphoma staging.×ArticlesLogInCasesSignUpCoursesQuizDonateAbout×MenuSearchADVERTISEMENT:Radiopaediaisfreethankstooursupportersandadvertisers.BecomeaGoldSupporterandseenoads.ArticlesCasesCoursesLogInLoginSignup{"url":"/signup-modal-props.json?lang=us\u0026email="}ArticlesCasesCoursesQuizAboutRecentEditsGoad-freeSearchDiffuselargeBcelllymphomaLastrevisedbyDrYairGlick◉on15Oct2021EditarticleViewrevisionhistoryReportproblemwithArticleCitation,DOIandarticledataCitation:Deng,F.,Glick,Y.DiffuselargeBcelllymphoma.Referencearticle,Radiopaedia.org.(accessedon19Oct2021)https://doi.org/10.53347/rID-70781DOI:https://doi.org/10.53347/rID-70781Permalink:https://radiopaedia.org/articles/70781rID:70781Articlecreated:04Sep2019byDrFrancisDeng◉Revisions:3timesby3users-seefullrevisionhistorySystems:Oncology,HaematologySections:-Tags:cases,refsSynonyms:DiffuselargeB-celllymphoma,nototherwisespecifiedURLofArticleDiffuselargeBcelllymphoma isthemostcommonsubtypeofnon-Hodgkinlymphoma.EpidemiologyAssociationsDiffuselargeBcelllymphomaissometimesassociatedwithimmunodeficiency,includingacquiredimmunodeficiencysyndrome.PathologyClassificationIn2016WHOclassificationoflymphoidneoplasms,diffuselargeBcelllymphoma,nototherwisespecified(NOS),isatypeofmatureBcellneoplasmandincludestwomolecularsubgroupsindicatingcelloforigin:germinalcenterBcelltypeactivatedBcelltypeInaddition,diffuselargeBcelllymphomaswithcertainmolecular/cytogeneticfeaturespreviouslycalled"double-hit"or"triple-hit"lymphomasaswellasthoseresemblingBurkittlymphomaarenowclassifiedtogetheraseitherofthefollowingentities1:high-gradeB-celllymphomawithMYCandBCL2and/orBCL6rearrangements high-gradeB-celllymphoma,nototherwisespecifiedThereareotherwisemultiplespecifiedtypesofdiffuselargeBcelllymphoma:T-cell/histiocyte-richlargeBcelllymphomaprimarydiffuselargeBcelllymphomaofthecentralnervoussystemprimarycutaneousdiffuselargeBcelllymphoma,

Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin's lymphoma (NHL) that requires treatment at initial diagnosis. Treatment decisions may be ...Clipboard,SearchHistory,andseveralotheradvancedfeaturesaretemporarilyunavailable.SkiptomainpagecontentCOVID-19InformationPublichealthinformation(CDC)Researchinformation(NIH)SARS-CoV-2data(NCBI)Preventionandtreatmentinformation(HHS)Español AccesskeysNCBIHomepageMyNCBIHomepageMainContentMainNavigationSearch:SearchAdvancedClipboardUserGuideSaveEmailSendtoClipboardMyBibliographyCollectionsCitationmanagerDisplayoptionsDisplayoptionsFormatAbstractPubMedPMIDSavecitationtofileFormat:Summary(text)PubMedPMIDAbstract(text)CSVCreatefileCancelEmailcitationSubject:1selecteditem:19291532-PubMedTo:Format:SummarySummary(text)AbstractAbstract(text)MeSHandotherdataSendemailCancelAddtoCollectionsCreateanewcollectionAddtoanexistingcollectionNameyourcollection:Namemustbelessthan100charactersChooseacollection:UnabletoloadyourcollectionduetoanerrorPleasetryagainAddCancelAddtoMyBibliographyMyBibliographyUnabletoloadyourdelegatesduetoanerrorPleasetryagainAddCancelYoursavedsearchNameofsavedsearch:Searchterms:TestsearchtermsWouldyoulikeemailupdatesofnewsearchresults?SavedSearchAlertRadioButtonsYesNoEmail:(change)Frequency:MonthlyWeeklyDailyWhichday?ThefirstSundayThefirstMondayThefirstTuesdayThefirstWednesdayThefirstThursdayThefirstFridayThefirstSaturdayThefirstdayThefirstweekdayWhichday?SundayMondayTuesdayWednesdayThursdayFridaySaturdayReportformat:SummarySummary(text)AbstractAbstract(text)PubMedSendatmost:1item5items10items20items50items100items200itemsSendevenwhentherearen'tanynewresultsOptionaltextinemail:SaveCancelCreateafileforexternalcitationmanagementsoftwareCreatefileCancelYourRSSFeedNameofRSSFeed:Numberofitemsdisplayed:510152050100CreateRSSCancelRSSLinkCopyFulltextlinksElsevierScienceFulltextlinksActionsCiteFavoritesDisplayoptionsDisplayoptionsFormatAbstractPubMedPMIDSharePermalinkCopyPagenavigationTitle&authorsAbstractSimilara

MenuNewsReferenceSlideshowsQuestions&AnswersMedicationsFindanOncologistOverview&FactsRisks&PreventionSymptoms&SignsCancerTypesDiagnosis&TestsYourCancerCareTeamCancerTreatmentCutting-EdgeTreatmentsLiving&ManagingRemission&RecurrenceSupport&ResourcesAllGuideTopicsLymphomaHodgkin'sLymphomaNon-Hodgkin'sLymphomaLeukemiaChildhoodLeukemiaPolycythemiaVeraChronicMyeloidLeukemiaMyelodysplasticSyndromeAcuteLymphoblasticLeukemiaBook:TakeControlofYourCancerRiskChronicLymphocyticLeukemiaMultipleMyelomaRadiationTherapyChemotherapyFindaHematologistCancerHealthCenterCancerA-ZGuideCancerLeukemia&LymphomaMenuMedicallyReviewedbyNehaPathak, MDonFebruary16,2021YourGuideToDiffuseLargeB-CellLymphomaCausesSymptomsGettingaDiagnosisQuestionsforYourDoctorTreatmentTakingCareofYourselfWhattoExpectGettingSupportDiffuselargeB-celllymphoma,orDLBCL,isacancerthatstartsinwhitebloodcellscalledlymphocytes.Itusuallygrowsinlymphnodes--thepea-sizedglandsinyourneck,groin,armpits,andelsewherethatarepartofyourimmunesystem.Itcanalsoshowupinotherareasofyourbody.DLBCLgrowsfast,but3outof4peoplearedisease-freeaftertreatment,andabouthalfarecured.Andresearchersareworkingtomaketreatmentsevenbetter.Therearetwotypesoflymphoma:Hodgkin'sandnon-Hodgkin's.Theybehave,grow,andrespondtotreatmentdifferently.DLBCListhemostcommonnon-Hodgkin'slymphoma.AndthereareseveraltypesofDLBCL.It'snormaltohaveworriesandquestionsaboutanyseriouscondition.Learnaboutyourtreatmentoptions,andseekoutfamilyandfriendsforsupport.Theycanhelpyougetthroughtheemotionalandphysicalchallengesahead.CausesDoctorsdon'tknowwhatcausesDLBCLandothernon-Hodgkin'slymphomas.Theydoknowthatyouaremorelikelytogetthemifyou're:Middle-agedorolder(onaverage,peoplearediagnosedwithDLBCLat64yearsold)AmanNotAsianorAfrican-AmericanYourchancesofgettingDLBCLmayalsogoupifyouhaveanautoimmunedisease,oryourimmunesystemisweakenedinanotherway.Ifyou'vebeentreatedwithbothradiationandchemotherapybefore,oryou'vebeenexposedtohigherlevelsofradiationorcertainchemicals,youroddsarehigher,too.Sympt

Ann Arbor Staging System · M+ = marrow · L+ = lung · H+ = liver · P+ = pleura · O+ = bone · D+ = skin and subcutaneous tissue.SurgicalPathologyCriteria–SearchThisSiteOnlyStanfordMedicalSitesWaystoGiveFindaPersonAlumniLaneLibraryWaystoGiveFindaPersonDiffuseLargeBCellLymphomaGrading/Staging/ReportDiffuselargeBcelllymphomasnotcurrentlygradedPreviously,theimmunoblasticvariantwasconsideredhighgradeSubsequentstudieshaveshownnodifferenceinprognosisAdverseprognosticfactorsreportedincludeHighprolferationratemeasuredbyKi67stainingbcl2expressionp53overexpressionAnnArborStagingSystemStageIIifinvolvementofasinglelymphnoderegionIEifinvolvementofasingleextralymphaticorganorsiteStageIIIIiftwoormorelymphnoderegionsonsamesideofdiaphragmIIEiflocalizedinvolvementofanextralymphaticorganorsiteandoneormorelymphnoderegionsonthesamesideofthediaphragmStageIIIIIIifInvolvementoflymphnoderegionsonbothsidesofthediphragmIIISifspleeninvolvedIIIEifextralymphaticsiteinvolvedStageIVDiffuseordisseminatedinvolvementofoneormoreextralymphaticorgansortissues,withorwithoutassociatedlymphnodeinvolvementSystemicSymptomsin6monthsprecedingadmissionFever,nightsweats,10%weightlossA=absentB=presentExtranodalsitesarealsodesignatedM+=marrowL+=lungH+=liverP+=pleuraO+=boneD+=skinandsubcutaneoustissueAlthoughoriginallydesignedforHodgkinlymphoma,theAnnArborSystemisalsousedfornon-Hodgkinlymphomas.Thepathologyreportshouldcontainthefollowinginformation:DiagnosisintheWorldHealthOrganization(WHO)classificationEquivalentdiagnosisinotherclassificationsusedbyrelevantcliniciansResultsofsupplementarystudiesifperformedRelationshiptootherspecimensfromthesamepatientInformationrelevanttostagingifavailableYouareHere:StanfordMedicine»SchoolofMedicine»Departments»SurgicalPathologyCriteria»DiffuseLargeBCellLymphomaNavigationforThisSection:SurgicalPathologyCriteriaDiagnosticCriteriaSupplementalStudiesDifferentialDiagnosisClinicalGrading/Staging/ReportClassification/ListsBibliographyPrintableVersionAdditionalLinks:GeneralLinksSurgicalPath